CervoMed (CRVO) Stock Jumps 32% After Director Buys $3M – Time to Buy?

TLDR

• CervoMed (CRVO) jumped 32.3% in premarket trading Tuesday after a director purchase was disclosed
• Director Joshua Boger bought 955,414 shares at $3.14 per share on June 11 via private placement
• The total purchase was worth approximately $3 million through the Joshua S. Boger 2021 Trust
• Each unit included one common share, one Series B warrant, and one Series C warrant
• H.C. Wainwright has a Buy rating on CRVO with a $25.00 price target

CervoMed (CRVO) stock jumped 32.3% in premarket trading on Tuesday after a Form 4 filing revealed director Joshua Boger had made a multi-million dollar purchase of the company’s stock.

CervoMed Inc., CRVO

Boger, through the Joshua S. Boger 2021 Trust, bought 955,414 shares at $3.14 per share on June 11. The total transaction came to roughly $3 million.

The stock had been under pressure before this filing. CRVO was trading at $2.48 before the news broke, down around 15% over the prior week and off 70% over the past six months.

The purchase was made as part of a private placement that CervoMed says is expected to generate around $10.5 million in gross proceeds. The deal was structured under a securities purchase agreement dated June 9 with Boger’s trust and other accredited investors.

Each unit in the placement came with one share of common stock, one Series B warrant, and one Series C warrant. The Series B warrants carry an exercise price of $3.32, are immediately exercisable, and expire June 11, 2031. The Series C warrants have an exercise price of $3.14, are also immediately exercisable, and expire June 11, 2027.

CEO John J. Alam also participated in the financing, making this a notable insider-driven deal at the leadership level.

Ownership After the Deal

Following the transaction, Boger now holds 1,795,865 shares indirectly through two trusts — the JSB 2021 Trust and The Amy S. Boger 2021 Trust — and another 216,817 shares directly.

The warrants include an ownership cap. Boger and his affiliates cannot own more than 19.99% of CervoMed’s outstanding common stock upon exercising the warrants. If that threshold would be breached, he can instead exercise for pre-funded warrants under the same restrictions.

CervoMed’s market cap sat at $23.42 million before the premarket move. InvestingPro pegs the fair value at $3.40, suggesting the stock was trading below that level going into Tuesday.

What Analysts Are Saying

H.C. Wainwright reiterated a Buy rating on CRVO with a $25.00 price target. That call came after CervoMed presented data from its Phase 2b RewinD-LB trial of neflamapimod at the AD/PD 2026 Conference.

The trial is studying neflamapimod for dementia with Lewy bodies. Data from the trial showed patients with lower plasma pTau181 levels saw greater clinical benefits from the treatment.

Separately, CervoMed shareholders approved all proposals at the company’s 2026 Annual Meeting, including the election of eight directors. Boger was among those re-elected to the board.

As of the Form 4 filing, Boger’s trust holds 1,600,117 shares, while The Amy S. Boger 2021 Trust holds 195,748 shares, both of which he manages as sole trustee.

The post CervoMed (CRVO) Stock Jumps 32% After Director Buys $3M – Time to Buy? appeared first on CoinCentral.